What is MindMaze Therapeutics Holding Current Ratio?
MindMaze Therapeutics HoldingCHIX:MMTXZ +4.74%15 Current Ratio is 1.20 as of Dec. 2025, which is at its 10-year median of 1.20. GuruFocus rates CHIX:MMTXZ with a GF Score™ of 15/100. The stock has 2 warning signs investors should review. Among 1,412 Biotechnology companies, MindMaze Therapeutics Holding ranks worse than 80.95% on this metric.
MindMaze Therapeutics Holding has a current ratio of 1.20. It generally indicates good short-term financial strength.
The historical rank and industry rank for MindMaze Therapeutics Holding's Current Ratio or its related term are showing as below:
CHIX:MMTXz'
s Current Ratio Range Over the Past 10 Years
Min: 1.2 Med: 1.2 Max: 1.2
Current: 1.2
During the past 2 years, MindMaze Therapeutics Holding's highest Current Ratio was 1.20. The lowest was 1.20. And the median was 1.20.
CHIX:MMTXz's Current Ratio is ranked worse than 80.95% of 1412
companies
in the Biotechnology industry
Industry Median: 3.9
vs CHIX:MMTXz: 1.20
MindMaze Therapeutics Holding (CHIX:MMTXz) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
MindMaze Therapeutics Holding Current Ratio Related Terms
MindMaze Therapeutics Holding Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindMaze Therapeutics Holding Current Ratio Chart
MindMaze Therapeutics Holding Annual Data
Trend
Dec24
Dec25
Current Ratio
0.00
1.20
MindMaze Therapeutics Holding Semi-Annual Data
Dec24
Dec25
Current Ratio
0.00
1.20
CHIX:MMTXZ vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, MindMaze Therapeutics Holding's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MindMaze Therapeutics Holding Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MindMaze Therapeutics Holding's Current Ratio distribution charts can be found below:
* The bar in red indicates where MindMaze Therapeutics Holding's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindMaze Therapeutics Holding (CHIX:MMTXZ) has a Current Ratio of 1.20 as of Dec. 2025. This is near median its historical median of 1.20. Over the past decade, MindMaze Therapeutics Holding's Current Ratio has ranged from 1.20 to 1.20. According to the industry distribution chart, MindMaze Therapeutics Holding ranks #1143 out of 1412 companies in the Biotechnology industry, placing it in the top 80.9%.
Is MindMaze Therapeutics Holding's Current Ratio too high?
MindMaze Therapeutics Holding's current Current Ratio of 1.20 is near median its 10-year median of 1.20. Over the past 10 years, this metric has ranged from a low of 1.20 to a high of 1.20. The Biotechnology industry median Current Ratio is 3.90. MindMaze Therapeutics Holding's value of 1.20 is 69.2% below this industry median. Based on the distribution chart, MindMaze Therapeutics Holding ranks #1143 out of 1412 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MindMaze Therapeutics Holding has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, MindMaze Therapeutics Holding ranks #1143 out of 1412 companies for Current Ratio. This places MindMaze Therapeutics Holding in the lower half of its industry. The industry median Current Ratio is 3.90. MindMaze Therapeutics Holding's value of 1.20 is 69.2% below this benchmark. Historically, MindMaze Therapeutics Holding's own Current Ratio has ranged from 1.20 to 1.20 over the past decade. While the company's 10-year median is 1.20 vs. the industry median of 3.90, MindMaze Therapeutics Holding has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.90, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MindMaze Therapeutics Holding's current Current Ratio of 1.20 is 69.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MindMaze Therapeutics Holding's current Current Ratio is 1.20, which is near median its own 10-year median of 1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (CHIX:MMTXZ) has a current Current Ratio of 1.20. The current Current Ratio is 1.20, which is near median its 10-year median of 1.20 and 69.2% below the Biotechnology industry median of 3.90. MindMaze Therapeutics Holding's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For MindMaze Therapeutics Holding (CHIX:MMTXZ), the current Current Ratio is 1.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MindMaze Therapeutics Holding Business Description
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
15GF Score
Get the complete analysis for CHIX:MMTXZ
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:MMTXZ has been successfully added to your 